Clinical Trials · NCT05890976

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

Name: Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Semaglutide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Novo Nordisk A/S
Enrollment: 200
Start date: May 2023
Locations: 16 sites, China
Primary endpoint: Relative Change in Body Weight

View Semaglutide compound reference